Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis

If a subject has received any of the following treatments, the indicated washout period prior to randomization must be followed:

1. Oral or injectable azathioprine, gold, D-Penicillamine, cyclosporine, anakinra, etanercept, parenteral or intra-articular corticosteroids: 30 days
2. Leflunomide: 6 months unless an active washout with Cholestyramine has been performed
3. Mycophenolate mofetil, cyclophosphamide, tacrolimus or other immunosuppressant: 3 months
4. Adalimumab, Infliximab, Golimumab, Certolizumab pegol, Abatacept or Tocilizumab: 60 days
5. Rituximab or any B-cell depleting agent: 1 year